The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Novel treatment options for non-Hodgkin lymphoma
Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the findings from recent studies investigating treatment options for non-Hodgkin lymphoma. Dr Collins focuses on the POLARIX study (NCT03274492), which compares R-CHOP with polatuzumab vedotin plus R-CHP. Results indicate an increased progression-free survival (PFS) and a reduction in subsequent anti-lymphoma treatments. Dr Collins also discusses factors which may influence the future use of this treatment in diffuse large B-cell lymphoma (DLBCL). This interview took place at the 63rd American Society of Hematology Annual Meeting and Exposition, Atlanta, 2021.
